These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia. Tsukamoto S, Nakaseko C, Takeuchi M, Kumagai K, Komatsu T, Tanaka H, Hara S, Koizumi M, Imai H, Yokota A, Takeuchi M, Inokuchi K, Matsuura Y, Aotsuka N, Wakita H. Br J Haematol; 2013 Oct 02; 163(2):286-9. PubMed ID: 23862773 [No Abstract] [Full Text] [Related]
11. Comment on: Use of thrombopoietin receptor agonist (romiplostim) in neonatal autoimmune thrombocytopenia due to maternal immune thrombocytopenia. Mahat U, Talati R, Kodish E. Pediatr Blood Cancer; 2019 Jun 02; 66(6):e27706. PubMed ID: 30854752 [No Abstract] [Full Text] [Related]
12. Combined romiplostim and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy. Mitsuhashi K, Ishiyama M, Imai Y, Shiseki M, Mori N, Teramura M, Seshimo A, Motoji T. Br J Haematol; 2012 Sep 02; 158(6):798-800. PubMed ID: 22758388 [No Abstract] [Full Text] [Related]
19. Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura. Newland A. Eur J Haematol Suppl; 2009 Mar 02; (71):20-5. PubMed ID: 19200304 [Abstract] [Full Text] [Related]
20. New therapy options for chronic immune thrombocytopenic purpura: a breath of fresh air. Introduction. Francesco R. Eur J Haematol Suppl; 2009 Mar 02; (71):1-2. PubMed ID: 19200300 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]